Literature DB >> 19624312

Targeting mutant BRAF and KIT in metastatic melanoma: ASCO 2009 meeting report.

Vernon K Sondak1, Keiran Smalley.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19624312     DOI: 10.1111/j.1755-148X.2009.00593.x

Source DB:  PubMed          Journal:  Pigment Cell Melanoma Res        ISSN: 1755-1471            Impact factor:   4.693


× No keyword cloud information.
  4 in total

1.  Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells.

Authors:  Yongping Shao; Andrew E Aplin
Journal:  Cancer Res       Date:  2010-07-20       Impact factor: 12.701

2.  Multiplex mutation screening by mass spectrometry evaluation of 820 cases from a personalized cancer medicine registry.

Authors:  Carol Beadling; Michael C Heinrich; Andrea Warrick; Erin M Forbes; Dylan Nelson; Emily Justusson; Judith Levine; Tanaya L Neff; Janice Patterson; Ajia Presnell; Arin McKinley; Laura J Winter; Christie Dewey; Amy Harlow; Oscar Barney; Brian J Druker; Kathryn G Schuff; Christopher L Corless
Journal:  J Mol Diagn       Date:  2011-07-02       Impact factor: 5.568

3.  Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma.

Authors:  William D Tap; Ke-Wei Gong; Judy Dering; Yiou Tseng; Charles Ginther; Giovanni Pauletti; John A Glaspy; Richard Essner; Gideon Bollag; Peter Hirth; Chao Zhang; Dennis J Slamon
Journal:  Neoplasia       Date:  2010-08       Impact factor: 5.715

4.  Proteasomal degradation of Mcl-1 by maritoclax induces apoptosis and enhances the efficacy of ABT-737 in melanoma cells.

Authors:  Manoj K Pandey; Krishne Gowda; Kenichiro Doi; Arun K Sharma; Hong-Gang Wang; Shantu Amin
Journal:  PLoS One       Date:  2013-11-04       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.